Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study

Celsion Corporation CLSN announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study. The Company previously announced that the U.S. Food and Drug Administration designated the HEAT study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation, as a Fast Track Development Program.